Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk said Wegovy pill prescriptions have topped 3 million in about five months, while Lilly said Foundayo prescriptions are now "markedly higher" than the 20,000 reported six weeks ago. The article highlights intensifying competition in the GLP-1 obesity market, upcoming Medicare access to GLP-1 drugs for weight loss at $50 a month starting in July, and continued pipeline progress for Lilly's retatrutide and Novo's CagriSema. The news is broadly supportive for both companies' obesity franchises, though it also underscores pricing, access, and competitive pressure.

Analysis

The market is still underestimating how the GLP-1 pivot changes the competitive battlefield from “best molecule wins” to “best distribution + best persistence + best payer access wins.” Novo’s pill momentum matters less as a standalone revenue line than as proof that the franchise can still generate new starts despite losing share in injectables; that reduces the probability of a terminal multiple reset. The larger second-order effect is that Medicare access will pull more older, polypharmacy-heavy patients into the category, which structurally favors the product that is easiest to layer onto existing medication routines and has the least friction at the point of fill.

Humana is the cleanest near-term operational beneficiary because it becomes the gatekeeper for a population that is both high-intent and high-touch. That said, the economics of this pilot will likely be noisy in the first 1-2 quarters: utilization spikes can look bad before downstream medical savings show up, and any friction in prior auth or adherence could create headlines that pressure the whole class. For Cigna, the risk is not just lost drug margin; it is that exiting coverage concedes pricing and relationship leverage to rivals that can point to measurable outcomes.

For Novo, the key catalyst is not the pill alone but whether the company can convert label breadth into better persistence and payer willingness before Lilly’s convenience advantage hardens. If Medicare seniors adopt on convenience, Lilly can win share even with lower efficacy; if outcomes messaging resonates, Novo can claw back mix. Retatrutide is the longer-duration upside optionality, but its real strategic value is as a ceiling-raiser for the whole category, forcing Novo to defend its brand with a product ladder rather than a single hero asset.

Key Decisions for Investors

• Long HUM vs short CI for 3-6 months: Medicare GLP-1 processing should create incremental claims/administrative flow for Humana while Cigna’s employee-coverage pullback signals weaker willingness to underwrite obesity drug demand; target 10-15% relative outperformance with tight stop if utilization implementation is delayed.
• Buy NVO on 3-6 month weakness, ideally after any post-event fade: the pill validates franchise durability and the label-broadening card is underappreciated; risk/reward improves if shares de-rate on near-term share-grab concerns while FDA timing for CagriSema remains intact.
• Short dated downside hedge on CI or use put spreads into the Medicare rollout window: if peer utilization data comes in worse than expected or employers cite the pilot to justify broader exclusions, the market will likely punish health-plan names with obesity-drug exposure.
• Pair trade long NVO / short a basket of obesity-exposed payers if Medicare adoption exceeds expectations: thesis is that improved access shifts margin capture toward manufacturers with the strongest patient persistence and labeling, while payers absorb the near-term cost.
• Avoid chasing Lilly here unless retatrutide data is de-risked by broader payer commentary: the market already discounts convenience leadership, but the cleaner upside catalyst is a stronger-than-expected senior adoption curve or explicit direct-to-consumer monetization path.